- Company meeting enrollment objectives
- European pharmaceutical executive joins the board of directors
- Financial results for the third quarter
- Solid finances: $44 million in liquidities
MONTREAL, Oct. 13 /CNW Telbec/ - Theratechnologies (TSX: TH) announced
today its financial results for the third quarter ended August 31, 2005 and
reviewed recent highlights.
"During the third quarter, we continued to make solid progress on all
fronts and in particular with our principal objective, which is to bring
TH9507 to market as soon as possible" said Yves Rosconi, President and Chief
Executive Officer of Theratechnologies. "More specifically, the enrollment for
our Phase 3 study in HIV-associated lipodystrophy which started at the end of
June is now well underway and we are confident that we will reach our
previously announced goal of 400 patients to complete enrollment by the end of
the first quarter of 2006".
"In other developments, we added valuable, complementary expertise to our
board in August with the appointment of a new member from the European and
international pharmaceutical industry. In financial terms, we ended the
quarter with $44 million in liquidities, sufficient to sustain our operations
for the next two years", Mr. Rosconi noted.
"Looking to the longer-term prospects for Theratechnologies, we will
complete the evaluation of our product pipeline by the end of the year. We
also plan to communicate the new directions we envisage for the Company at the
conclusion of an in-depth strategic review that is presently in process", he
concluded.
Operating highlights:
TH9507: Phase 3 program in HIV-associated lipodystrophy
The patient enrollment for the Phase 3 study in HIV-associated
lipodystrophy in the United-States is on plan. The enrollment rate is
currently 10 patients per week and is growing exponentially as additional U.S.
sites are steadily coming on stream. The enrollment rate will be boosted
further with the initiation of Canadian sites in the coming weeks. Most of the
38 sites selected for the study will be operational by the end of October. As
previously announced, the Company expects to conclude the enrollment of the
required 400 patients by the end of the first quarter of 2006 and announce
results in the second half of the year.
HIV-associated lipodystrophy is a serious metabolic syndrome that is
often associated with growth hormone deficiency. It is characterized by an
accumulation of visceral adipose tissue (VAT), dyslipidemia and glucose
intolerance. The condition is a risk factor for cardiovascular disease and
type 2 diabetes. First diagnosed in 1998, HIV-associated lipodystrophy is an
emerging disease and a growing affliction among HIV patients. There is
currently no approved therapy for this disease for which the market potential
in North America and Europe is estimated to be between US $425 million and US
$850 million annually.
Theratechnologies representatives will be attending the 7th International
Workshop on Adverse Drug Reactions and Lipodystrophy in HIV in Dublin,
Ireland, in mid-November. This annual event is the preeminent international
conference in the field of HIV-associated lipodystrophy, attracting experts
and key opinion leaders from around the globe.
In October, Mr. Yves Rosconi, President and Chief Executive Officer of
the Company, presented at BioContact 2005 conference in QuDebec City. His
presentation featured an update of the Company's Phase 3 program with TH9507
and he outlined the attractive market opportunity for Theratechnologies
presented by HIV-associated lipodystrophy.
Appointment to the board of directors
In August, the Company's board of directors welcomed a new member,
Mr. Bernard Reculeau, who, until recently, was Senior Vice President
Pharmaceutical Operations of Paris-based sanofi-aventis for the
InterContinental Region. Mr. Reculeau brings 21 years of European and
international pharmaceutical industry experience to Theratechnologies, which
adds a valuable, complementary perspective to the board.
$44 million in liquidities
At August 31, 2005, liquidities (cash, cash equivalents as well as bonds)
amounted to $42.2 million, and tax credits and grants receivable amounted to
$1.4 million, for a total of $43.6 million. Based on the current burn rate,
the Company should be able to fund its operations for the next 2 years.
Sale of investment in Celmed BioSciences
On June 20, the Company completed the sale of its 37% interest in Celmed
BioSciences, a privately held oncology company, for total consideration of up
to $8.4 million. Total consideration includes an upfront payment of
$2.8 million and milestone payments tied to the success of Celmed's lead
products.
MANAGEMENT'S DISCUSSION AND ANALYSIS OF RESULTS OF OPERATIONS AND
FINANCIAL CONDITION:
Consolidation and investments
The consolidated financial statements include the accounts of
Theratechnologies and its subsidiaries. On June 20, 2005, the Company closed
the sale of its 37.3% investment in Celmed, a private company engaged in the
field of oncology. Prior to that date, Theratechnologies' consolidated results
included Celmed's results (see note 5 in the notes to the consolidated
financial statements). For comparison purposes, results without Celmed are
presented as additional information in the Management's discussion and
analysis of results of operations and financial condition.
Summary of operating results
Consolidated revenues for the three-month period ended August 31, 2005
amounted to $409,000, compared to $585,000 ($516,000 without Celmed) for the
same period in 2004. The decrease in revenues for the third quarter of 2005 is
attributed to a decrease in interest revenues resulting from reduced
liquidities (cash and cash equivalents as well as bonds) and from a lower
yield from investments due to lower interest rates. For the nine-month period
ended August 31, 2005, consolidated revenues were $16,142,000, compared to
$2,146,000 ($1,590,000 without Celmed) for the corresponding period in 2004.
The increase in revenues during the nine-month period is essentially due to an
amount of $14,640,000 (US$12,000,000) received in connection with the
Company's December 2004 agreement with ALZA to terminate three co-development
projects using ALZA's Macroflux(R) transdermal technology.
Consolidated research and development (R&D) expenditures, before tax
credits and grants, for the third quarter of 2005, totalled $3,855,000,
compared to $3,311,000 ($2,805,000 without Celmed) in 2004. The increase in
R&D expenditures for the quarter was due to expenditures related to the TH9507
Phase 3 study in HIV-associated lipodystrophy, in which a first patient was
treated in June 2005. For the nine-month period ended August 31, 2005, R&D
expenses were $10,321,000, compared to $14,876,000 ($10,845,000 without
Celmed). The R&D spending, for the nine-month period ended August 31, 2005,
was comparable to the same period in 2004, however the previous year expenses
included programs involving ThPTH and TH0318, a GLP-1 (glucagon-like peptide-
1) analogue.
For the third quarter of 2005, general and administrative expenses,
selling and market development expenses, patents and amortization of other
assets (SG&A) were $1,805,000, compared to $1,803,000 ($1,613,000 without
Celmed) for the same period in 2004. The increase in SG&A expenses is mainly
due to preparations required for late-stage development and future
commercialization of TH9507. For the nine-month period ended August 31, 2005,
SG&A expenses amounted to $5,926,000 ($5,482,000 before the adjustment to book
value of patents and deferred development expenses referred to below),
compared to $6,644,000 ($4,627,000 without Celmed) for the same period in
2004. This increase is due to the expenses related to the late-stage
development of TH9507 and to a write off of $444,000 recorded in May 2005 of
certain patent costs and deferred development expenses, following management's
reassessment of its strategy regarding non-core products and the related
patent portfolio.
For the third quarter of 2005, the proportionate share in loss of
companies under significant influence was estimated to be $153,000 based on
second quarter results of 2005, compared to $1,137,000 in 2004. The decrease
is due to the fact that Celmed's losses were no longer recognized during the
third quarter of 2005, following the sale of the Company's interest in Celmed
in June 2005. For the nine-month period ended August 31, 2005, the
proportionate share in loss of Celmed and Andromed was $6,602,000, compared to
$1,630,000 in 2004. The increase is due to two factors. First, the
proportionate share in the losses of Celmed in 2005 is greater than that of
2004, as the latter includes Celmed's results from July 2nd only (see note 5
in the notes to the consolidated financial statements). Second, the
proportionate share in 2005 is higher than that of 2004 due to a non-cash
write down, net of related income taxes, of $9,685,000 recorded by Celmed at
May 31, 2005 in connection with intellectual property acquired from NewBiotics
in 2004.
On June 20, 2005, the Company completed the sale of its 37,3% interest in
Celmed for total proceeds of up to $8,400,000. The proceeds include an upfront
payment of $2,811,000, as well as milestone payments tied to the success of
Celmed's more advanced products totalling $5,589,000. The milestone payments
will be recorded once the related milestones are reached. Consequently, a non-
cash write down of $2,659,000 was recorded in the second quarter of 2005.
Reflecting the variations in revenues and expenses described above, the
Company recorded an operating loss, for the three-month period ended
August 31, 2005, of $5,065,000 (before proportionate share in loss of a
company under significant influence, gains on investments in companies and
gains on dilution, non-controlling interest and discontinued operations),
compared to an operating loss of $4,289,000 for the same period in 2004. The
net loss for the third quarter of 2005 was $5,218,000, compared to a net loss
of $4,150,000 in 2004. For the nine-month period ended August 31, 2005, the
net loss was therefore $8,692,000, compared to $11,943,000 in 2004.
Quarterly financial information
The selected financial information provided below is derived from the
Company's unaudited quarterly financial statements for each of the last eight
quarters. This quarterly information has been restated pursuant to the change
in accounting policy related to stock-based remuneration and other payments
described in the 2004 Annual Report, and in order to account for discontinued
operations. This information includes Celmed's results until July 2, 2004.
(See note 5 in the notes to the consolidated financial statements).
<<
-------------------------------------------------------------------------
-------------------------------------------------------------------------
2005 2004
-------------------------------------------------------------------------
Q3 Q2 Q1 Q4
-------------------------------------------------------------------------
Revenues $ 409 $ 631 $ 15,102 $ 503
Operating
earnings (loss) (1) $ (5,065) $ (4,784) $ 10,418 $ (4,655)
Earnings (loss) from
continuing
operations (2) $ (5,218) $ (12,745) $ 9,271 $ (10,873)
Net earnings (loss) $ (5,218) $ (12,745) $ 9,271 $ (10,873)
Basic and dilute
earnings (loss)
per share:
Continuing
activities (2) $ (0.15) $ (0.36) $ 0.26 $ (0.31)
Net earnings (loss) $ (0.15) $ (0.36) $ 0.26 $ (0.31)
-------------------------------------------------------------------------
-------------------------------------------------------------------------
-------------------------------------------------------------------------
-------------------------------------------------------------------------
2004 2003
-------------------------------------------------------------------------
Q3 Q2 Q1 Q4
-------------------------------------------------------------------------
Revenues $ 585 $ 782 $ 779 $ 897
Operating
earnings (loss) (1) $ (4,289) $ (6,832) $(7,094) $ (7,805)
Earnings (loss) from
continuing
operations (2) $ (4,137) $ (6,139) $(1,731) $ (7,771)
Net earnings (loss) $ (4,150) $ (5,910) $(1,883) $ (14,079)
Basic and diluted
earnings (loss)
per share:
Continuing
activities (2) $ (0.12) $ (0.17) $ (0.06) $ 0.25
Net earnings (loss) $ (0.12) $ (0.17) $ (0.06) $ (0.46)
-------------------------------------------------------------------------
-------------------------------------------------------------------------
(1) Before restructuring costs, proportionate share in loss of a company
under significant influence, gains on investments in companies and
gains on dilution, discontinued operations and non-controlling
interest
(2) Net of non-controlling interest
Financial position
Theratechnologies continues to be in a sound cash position. At August 31,
2005, liquidities, namely cash and cash equivalents as well as bonds, amounted
to $42,224,000 and tax credits and grants receivable amounted to $1,432,000,
for a total of $43,656,000.
For the three-month period ended August 31, 2005, the burn rate from
operating activities, excluding changes in operating assets and liabilities,
was $4,700,000, compared to a burn rate of $3,882,000 ($3,265,000 without
Celmed) in 2004, reflecting the higher R&D expenses described above. For the
nine-month period ended August 31, 2005, cash from operating activities,
excluding changes in operating assets and liabilities, was $2,055,000,
reflecting the payment received from ALZA Corporation, compared to a burn rate
of $16,490,000 ($11,655,000 without Celmed) in 2004.
At October 12, 2005, the number of shares issued and outstanding was
35,549,019, while outstanding options granted under the stock option plan were
2,629,829. In addition, 1,280,000 warrants were outstanding.
During the quarter, there were no material changes in contractual
obligations, other than in the ordinary course of business.
Economic and industry factors were substantially unchanged from those
reported in the Company's 2004 annual report.
About Theratechnologies
Theratechnologies (TSX: TH) is a Canadian biopharmaceutical company
engaged in the discovery and development of therapeutic peptides in the field
of endocrinology and metabolism. The Company uses proprietary discovery
technologies to expand its product portfolio. The most advanced clinical
program (Phase III) targets HIV-associated lipodystrophy with its lead
compound, TH9507 (ThGRF). The Company is investigating other potential
indications for TH9507 and it also has an interesting product pipeline
targeting type 2 diabetes.
Additional information about Theratechnologies
Further information relating to Theratechnologies is available on the
Company's website at http://www.theratech.com/ . The Company is listed on the
Toronto Stock Exchange under the symbol TH. Additional information, including
the Company's Annual Information Form, is available on SEDAR at
www.sedar.com .
This press release contains forward-looking statements regarding the
clinical development of TH9507 and its future commercialization in the
indication described above. Such statements inherently involve numerous risks
and uncertainties, including the availability of funds and resources, the
success and timely completion of clinical trials and the granting of the
necessary authorizations. Actual future results may differ materially from the
anticipated results. Investors are cautioned against placing undue importance
on forward-looking information contained herein and should consult the
Company's 2004 Annual Report, which contains a more exhaustive analysis of
risks and uncertainties connected to the businesses of the Company.
<<
THERATECHNOLOGIES INC.
CONSOLIDATED BALANCE SHEET
(in thousands of dollars)
--------------------------------------------------------------------------
--------------------------------------------------------------------------
August 31 November 30
2005 2004
-------------------------
--------------------------------------------------------------------------
(unaudited) (audited)
Assets
Current assets:
Cash and cash equivalents $ 4,769 $ 436
Bonds 11,796 17,513
Accounts receivable 389 395
Tax credits receivable 1,432 754
Research supplies 2,649 1,542
Prepaid expenses 698 202
------------------------------------------------------------------------
------------------------------------------------------------------------
21,733 20,842
Bonds 25,659 24,105
Investments in public companies
(market value : $1,530 in 2005;
$3,026 in 2004) 907 1,362
Investment in a private company (note 5) - 11,367
Property and equipment 2,220 2,234
Other assets (note 2) 7,728 8,040
--------------------------------------------------------------------------
--------------------------------------------------------------------------
$ 58,247 $ 67,950
--------------------------------------------------------------------------
--------------------------------------------------------------------------
Liabilities and Shareholders' Equity
Current liabilities:
Accounts payable and accrued liabilities $ 3,672 $ 4,996
Shareholders' equity:
Capital stock (note 3) 155,654 155,594
Contributed surplus 2,510 2,257
Deficit (103,589) (94,897)
------------------------------------------------------------------------
54,575 62,954
$ 58,247 $ 67,950
--------------------------------------------------------------------------
--------------------------------------------------------------------------
See accompanying notes to unaudited consolidated financial statements.
THERATECHNOLOGIES INC.
CONSOLIDATED STATEMENT OF EARNINGS
PERIODS ENDED AUGUST 31
(in thousands of dollars, except per share amounts) (unaudited)
--------------------------------------------------------------------------
--------------------------------------------------------------------------
Third quarter Nine months
2005 2004 2005 2004
--------------------------------------------------------------------------
Revenues:
Royalties,
technologies
and other
(note 5) $ 20 $ 75 $ 14,850 $ 214
Interest 389 510 1,292 1,932
------------------------------------------------------------------------
------------------------------------------------------------------------
409 585 16,142 2,146
Operating costs
and expenses:
Research and
development 3,855 3,311 10,321 14,876
Tax credits (186) (240) (674) (1,159)
------------------------------------------------------------------------
3,669 3,071 9,647 13,717
General and
administrative 1,387 1,348 4,074 5,335
Selling and
market
development 210 273 795 719
Patents and
amortization of
other assets
(note 2) 208 182 1,057 590
------------------------------------------------------------------------
------------------------------------------------------------------------
5,474 4,874 15,573 20,361
--------------------------------------------------------------------------
Operating (loss)
earnings before
undernoted items (5,065) (4,289) 569 (18,215)
Proportionate
share in loss of
companies under
significant
influence (153) (1,137) (6,602) (1,630)
(Loss) gains on
investments in
companies and
gains on dilution
(note 5) - 1,046 (2,659) 5,789
--------------------------------------------------------------------------
Loss from continuing
operations before
non-controlling
interest (5,218) (4,380) (8,692) (14,056)
(Loss) gain from
discontinued
operations
(note 6) - (22) - 109
Non-controlling
interest - 252 - 2,004
--------------------------------------------------------------------------
Net loss $ (5,218) $ (4,150) $ (8,692) $ (11,943)
--------------------------------------------------------------------------
--------------------------------------------------------------------------
Basic and diluted
loss per share
(note 3 b):
Continuing
operations net
of non-
controlling
interest $ (0.15) $ (0.12) $ (0.25) $ (0.35)
Net loss $ (0.15) $ (0.12) $ (0.25) $ (0.35)
--------------------------------------------------------------------------
--------------------------------------------------------------------------
Weighted average
number of
common shares
outstanding 35,549,019 35,476,423 35,529,213 34,141,433
--------------------------------------------------------------------------
--------------------------------------------------------------------------
See accompanying notes to consolidated financial statements.
THERATECHNOLOGIES INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
PERIODS ENDED AUGUST 31
(in thousands of dollars) (unaudited)
--------------------------------------------------------------------------
--------------------------------------------------------------------------
Third quarter Nine months
2005 2004 2005 2004
--------------------------------------------------------------------------
Cash flows from
operating
activities:
Net loss $ (5,218) $ (4,150) $ (8,692) $ (11,943)
Adjustments for:
Depreciation
of property
and equipment 156 90 431 623
Depreciation
of other
assets 119 125 802 393
Stock-based
compensation 90 192 253 709
Proportionate
share in loss
of companies
under
significant
influence 153 1,137 6,602 1,630
Loss (gains)
on investments
in companies
and gains
on dilution - (1,046) 2,659 (5,789)
Loss (gain)
from
discontinued
operations - 22 - (109)
Non-controlling
interest - (252) - (2,004)
------------------------------------------------------------------------
(4,700) (3,882) 2,055 (16,490)
Change in
operating
assets and
liabilities:
Interest
receivable
on bonds 364 151 410 112
Accounts
receivable (44) 291 6 143
Tax credits
receivable (186) (241) (678) (1,154)
Research
supplies 242 (334) (1,496) (60)
Prepaid
expenses (101) 197 (496) (349)
Accounts
payable and
accrued
liabilities (447) (324) (1,157) (2,086)
----------------------------------------------------------------------
(172) (260) (3,411) (3,394)
Cash used in
discontinued
operations - (18) - (424)
------------------------------------------------------------------------
(4,872) (4,160) (1,356) (20,308)
Cash flows from
financing
activities:
Share issue - - 60 15,721
Share issue
costs - (30) - (1,157)
------------------------------------------------------------------------
- (30) 60 14,564
Cash flows from
investing
activities:
Addition to
property and
equipment (79) (74) (459) (452)
Disposal of
property and
equipment - - - 122
Addition to
other assets (35) (315) (226) (702)
Acquisition of
bonds (3,542) - (10,931) (26,102)
Disposal of
bonds 3,133 2,814 14,684 32,158
Disposal of
shares in a
private company 2,565 - 2,561 -
Disposal of
shares in public
companies - - - 2,481
Net investments
related to
discontinued
operations - - - 10
Cash and cash
equivalents
related to
Celmed - (1,370) - (1,370)
------------------------------------------------------------------------
------------------------------------------------------------------------
2,042 1,055 5,629 6,145
--------------------------------------------------------------------------
Net change in
cash and cash
equivalents (2,830) (3,135) 4,333 401
Cash and cash
equivalents,
beginning of
period 7,599 3,589 436 53
--------------------------------------------------------------------------
--------------------------------------------------------------------------
Cash and cash
equivalents,
end of period $ 4,769 $ 454 $ 4,769 $ 454
--------------------------------------------------------------------------
--------------------------------------------------------------------------
See accompanying notes to consolidated financial statements.
See note 8 a) for supplemental cash flow information.
THERATECHNOLOGIES INC.
CONSOLIDATED STATEMENTS OF DEFICIT NINE-MONTH
PERIOD ENDED AUGUST 31
(in thousands of dollars) (unaudited)
--------------------------------------------------------------------------
--------------------------------------------------------------------------
2005 2004
--------------------------------------------------------------------------
Deficit, beginning of year $ (94,897) $ (70,922)
Net loss (8,692) (11,943)
Share issue costs - (1,171)
--------------------------------------------------------------------------
Deficit, end of period $ (103,589) $ (84,036)
--------------------------------------------------------------------------
--------------------------------------------------------------------------
See accompanying notes to consolidated financial statements.
THERATECHNOLOGIES INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
PERIODS ENDED AUGUST 31, 2005
(in thousands of dollars, except per share amounts) (unaudited)
--------------------------------------------------------------------------
--------------------------------------------------------------------------
1. Basis of presentation
The financial statements included in this report are unaudited and
reflect normal and recurring adjustments, which are in the opinion of the
Company, considered necessary for a fair presentation. These financial
statements have been prepared in conformity with Canadian generally accepted
accounting principles. The same accounting policies as described in the
Company's latest annual report have been used. However, these financial
statements do not include all disclosures required under generally accepted
accounting principles and accordingly should be read in connection with the
financial statements and the notes thereto included in the Company's latest
annual report. These interim financial statements have not been reviewed by
auditors.
2. Other assets
During the first half of 2005, management reassessed its strategy
regarding non-core products and the related patent portfolio. As a result, the
Company recorded a write off of $444 of certain patent costs and deferred
development expenses.
3. Capital stock
--------------------------------------------------------------------------
--------------------------------------------------------------------------
August 31 November 30
2005 2004
--------------------------------------------------------------------------
--------------------------------------------------------------------------
Authorized in unlimited number
and without par value:
Common shares
Preferred shares issuable in one
or more series
Issued:
35,549,019 common shares
(35,513,549 in 2004) $ 155,654 $ 155,594
--------------------------------------------------------------------------
--------------------------------------------------------------------------
During the second quarter of 2005, the Company issued 35,470 shares for
cash consideration of $60.
a) Stock-based compensation and other stock-based payments
The weighted-average fair value of the 415,000 options granted during the
nine-month period ended August 31, 2005 is $0.97 per option. The fair value of
the options granted during 2005 was estimated at the date of grant using the
Black-Scholes option pricing model with the following assumptions: risk- free
interest rate of 3.77%, expected dividend yield of nil, expected volatility of
51% and an average expected option life of 6 years.
b) Diluted loss per share
Diluted loss per share were not presented as the effect of options and
warrants would have been anti-dilutive. Furthermore, the exercise of options
and warrants would not have been considered in such computation since their
exercise prices were higher than the average market price during the reporting
periods of 2004 and 2005.
4. Royalties, technologies and other
In December 2004, the Company completed an agreement to terminate three
co-development projects using ALZA Corporation's Macroflux(R) transdermal
technology. The Company retains the rights to develop its molecules with all
other means of delivery and ALZA retains the commercialization rights to
Macroflux(R) with other molecules. In this regard, the Company received a
payment of $14,640 (US $12,000).
5. Loss (gains) on investments in companies and gains on dilution
2005:
On June 20, 2005, the Company completed the sale of its 37,3% interest in
Celmed BioSciences for total proceeds of up to $8,400. The acquirer is a group
of minority shareholders of Celmed. The proceeds include an upfront payment of
$2,811, as well as milestone payments tied to the success of Celmed's more
advanced products totalling $5,589. The milestone payments will be recorded
once the related milestones are reached. On May 31, 2005, the Company recorded
a reduction in value of $2 659 in relation to the sale of its shares in Celmed
on June 20, 2005.
2004:
During the quarters ended February 29, 2004 and May 31, 2004, the Company
realized gains on investments in companies of $1,929 and $89 respectively,
resulting from the sale of shares in public companies.
In January and February 2004, Celmed's institutional investors exercised
adjustment clauses in relation to their investment, thus reducing the
Company's interest in Celmed from 61.6% to 56.1%. In February 2004, Celmed
proceeded with the redemption for a nominal amount of shares of certain
shareholders because the milestones related to these shares were not achieved.
In April 2004, Celmed proceeded with the redemption of shares of a non-
controlling shareholder in connection with the sale of a US subsidiary. These
redemptions resulted in an increase of the Company's interest in Celmed to
59.7%. As a result of these transactions, the deferred gain of $3,762 at
November 30, 2003 was attributed to non-controlling interests, and the
adjustment to their interest resulted in a gain of $2,725, which is included
in the statement of earnings for the period ended February 29, 2004.
As a result of the issuance of shares by Celmed to acquire NewBiotics
Inc. on July 2, 2004, Theratechnologies' interest in Celmed was reduced from
59.7% to 42%. An adjustment clause in connection with the interest of founding
investors later reduced the Company's interest to 37.3%. The Company
recognized a gain of $1,046 on the transaction in the period ended August 31,
2004.
6. Discontinued operations
During the first quarter of 2004, Celmed studied the relevance of
pursuing its activities in the treatment of Parkinson's disease. In this
context, Celmed discontinued its development activities for this program. In
April 2004, Celmed disposed of the shares of its US subsidiary in the field of
neurology.
Consequently, operating results for these activities have been
reclassified under item "Discontinued operations". The results are shown
below:
--------------------------------------------------------------------------
--------------------------------------------------------------------------
Third quarter Nine months
2005 2004 2005 2004
--------------------------------------------------------------------------
--------------------------------------------------------------------------
Costs and
expenses:
General and
administrative $ - $ 22 $ - $ (20)
Research and
development - - - 322
Patents and
amortization
of other assets - - - 21
Gain on disposal
of subsidiary - - - (432)
--------------------------------------------------------------------------
(Loss) gain from
discontinued
operations $ - $ (22) $ - $ 109
--------------------------------------------------------------------------
--------------------------------------------------------------------------
(Loss) gain from
discontinued
operations
attributable to
parent company $ - $ (13) $ - $ 64
--------------------------------------------------------------------------
--------------------------------------------------------------------------
Non-controlling
interest before
discontinued
activities $ - $ 243 $ - $ 2,049
--------------------------------------------------------------------------
--------------------------------------------------------------------------
Loss from
continuing
operations, net
of non-
controlling
interest $ (5,218) $ (4,137) $ (8,692) $ (12,007)
--------------------------------------------------------------------------
--------------------------------------------------------------------------
7. Segmented information
--------------------------------------------------------------------------
Intersegment
adjustments
Therapeutic Cell Other and elimi-
peptides therapy segments nations Total
--------------------------------------------------------------------------
Third quarter ended
August 31, 2005
Revenues from
external customers $ 20 $ - $ - $ - $ 20
Loss from
continuing operations (5,065) - (153) - (5,218)
Net loss (5,065) - (153) - (5,218)
Total assets 57,849 - 907 (509) 58,247
Nine months ended
August 31, 2005
Revenues from
external customers $ 14,830 $ - $ - $ - $ 14,830
Revenues from companies
under significant
influence 20 - - - 20
Earnings (loss) from
continuing operations 569 (6,147) (455) (2,659) (8,692)
Net earnings (net loss) 569 (6,147) (455) (2,659) (8,692)
Total assets 57,849 - 907 (509) 58,247
--------------------------------------------------------------------------
Third quarter ended
August 31, 2004
Revenues from
external customers $ 69 $ - $ - $ - $ 69
Intersegment revenues 22 - - (16) 6
Loss from
continuing operations (3,684) (1,517) (234) 1,298 (4,137)
Net loss (3,684) (1,530) (234) 1,298 (4,150)
Total assets 58,316 17,392 1,206 (70) 76,844
Nine months ended
August 31, 2004
Revenues from
external customers $ 208 $ - $ - $ - $ 208
Intersegment revenues 64 - - (58) 6
Loss from
continuing operations (12,968) (5,909) (727) 7,597 (12,007)
Net Loss (12,968) (5,845) (727) 7,597 (11,943)
Total assets 58,316 17,392 1,206 (70) 76,844
--------------------------------------------------------------------------
8. Supplemental information
a) The following transactions were concluded by the Company and did not
impact cash flow.
--------------------------------------------------------------------------
--------------------------------------------------------------------------
August 31 August 31
2005 2004
--------------------------------------------------------------------------
--------------------------------------------------------------------------
Addition to property and equipment
financed by accounts payable and
accrued liabilities $ 207 $ 43
Addition to other assets financed by
accounts payable and accrued liabilities 4 756
Share issue cost financed by accounts
payable and accrued liabilities - 14
--------------------------------------------------------------------------
b) General and administrative expenses include a loss on exchange of $73
for the third quarter of 2005 (gain of $55 in 2004) and a loss of $76 for the
nine month period ended August 31, 2005 (gain of $95 in 2004).
>>
Theratechnologies: TH9507 Phase 3 study advancing rapidly
Earlier from Theratechnologies
- European pharmaceutical executive joins the Board of Theratechnologies
- Theratechnologies: Financial results for the second quarter and recent operating highlights
- Theratechnologies launches Phase III clinical trial for TH9507 (ThGRF) treating HIV-associated lipodystrophy
- Theratechnologies closes the sale of its investment in Celmed BioSciences
- Theratechnologies: four scientific posters at the Endocrine Society Annual Meeting
Later from Theratechnologies
- Theratechnologies' common shares now eligible for inclusion in the SMB Growth Stock Plan
- Market Regulation Services - Trading Halt - Theratechnologies Inc. - TH
- Market Regulation Services - Trade Resumption - Theratechnologies Inc. - TH
- Standard & Poor's annonce des modifications aux indices canadiens S&P/TSX
- "Undervalued" Theratechnologies Inc. (OTC: THTCF) (TSE: TH)
Follow Theratechnologies into a list and get an email when it puts out news.
Follow Theratechnologies